CD | UC | |

Patients; n (%) | 288 (56.8) | 219 (43.2) |

Females; n (%) | 163 (56.5) | 129 (58.9) |

Smoking history; n (%) | 110 (38.1) | 65 (29.6) |

Age at IBD diagnosis (years); mean±SD | 33.4±14.5 | 35.7±14.4 |

Disease duration (months); mean±SD | 95.4±74.3 | 97.1±86.4 |

SpA family history, n (%) | 8 (2.7) | 8 (3.6) |

Psoriasis; n (%) | 39 (13.5) | 25 (11.4) |

NIU; n (%) | 13 (4.5) | 4 (1.8) |

HLA-B27; n (%) | 10/121 (8.2) | 7/76 (9.2) |

CRP (mg/L); mean±SD | 9.8±7.4 | 7.1±5.7 |

Comorbidities | ||

Obesity; n (%) | 7 (2.4) | 13 (5.9) |

Diabetes; n (%) | 11 (3.8) | 7 (2.4) |

Hypertension; n (%) | 41 (14.2) | 26 (11.8) |

MetS; n (%) | 4 (1.3) | 8 (3.6) |

Hypercholesterolaemia; n (%) | 7 (2.4) | 7 (2.4) |

Continuous variables were presented as mean and SD and compared using the parametric unpaired t test or Student’s t-test when appropriate. Categorical variables were presented with absolute frequencies and percentages and were compared using the χ

^{2}test or Fisher’s exact test when appropriate. A p<0.05 was considered significant.CD, Crohn’s disease; CRP, C reactive protein; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; MetS, metabolic syndrome; NIU, non-infectious uveitis; SpA, spondyloarthritis; UC, ulcerative colitis.